| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ERLIN2 |
| Uniprot No | O94905 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 25-339aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMGSKIEEGHIGVYYRGGALLTSTSGPGFHL MLPFITSYKSVQTTLQTDEVKNVPCGTSGGVMIYFDRIEVVNFLVPNAVY DIVKNYTADYDKALIFNKIHHELNQFCSVHTLQEVYIELFDQIDENLKLA LQQDLTSMAPGLVIQAVRVTKPNIPEAIRRNYELMESEKTKLLIAAQKQK VVEKEAETERKKALIEAEKVAQVAEITYGQKVMEKETEKKISEIEDAAFL AREKAKADAECYTAMKIAEANKLKLTPEYLQLMKYKAIASNSKIYFGKDI PNMFMDSAGSVSKQFEGLADKLSFGLEDEPLETATKEN |
| 预测分子量 | 38 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ERLIN2重组蛋白的3篇参考文献示例(内容为模拟概括，建议根据实际研究补充具体文献信息)：
---
1. **文献名称**：*Structural and functional analysis of the Erlin2 protein complex in ER-associated degradation*
**作者**：Smith J, et al.
**摘要**：通过重组ERLIN2蛋白的体外表达和结构解析，研究发现ERLIN2与ERLIN1形成复合物，参与内质网相关降解(ERAD)过程，识别泛素化膜蛋白并促进其蛋白酶体降解，揭示了其C端结构域在寡聚化中的关键作用。
2. **文献名称**：*ERLIN2 mutations impair lipid homeostasis through disruption of sterol-regulated protein interactions*
**作者**：Lee S, et al.
**摘要**：利用重组ERLIN2蛋白进行体外互作实验，发现其与Insig-1蛋白结合并调控胆固醇代谢通路。突变分析表明，遗传性痉挛性截瘫相关突变会破坏重组ERLIN2的稳定性，导致内质网脂质信号传导异常。
3. **文献名称**：*Recombinant ERLIN2 facilitates identification of its role in regulating ryanodine receptor stability*
**作者**：Chen X, et al.
**摘要**：通过重组ERLIN2蛋白的功能研究，发现其通过结合并稳定内质网上的ryanodine受体(RyR)，抑制钙离子通道过度激活，提示ERLIN2在神经退行性疾病中的潜在保护机制。
---
**备注**：若需具体文献，建议在PubMed或Google Scholar中搜索关键词“ERLIN2 recombinant protein”“ERLIN2 structure/function”获取近年研究。ERLIN2相关研究多聚焦于内质网应激、脂代谢及神经退行性疾病机制。
**Background of ERLIN2 Recombinant Protein**
ERLIN2 (ER Lipid Raft-Associated 2), also known as SPFH2 or C8orf2. is a member of the SPFH (stomatin-prohibitin-flotillin-HflK/C) domain-containing protein family. It is predominantly localized in the endoplasmic reticulum (ER), where it plays critical roles in lipid raft organization, ER-associated degradation (ERAD), and cellular cholesterol homeostasis. ERLIN2 forms oligomeric complexes with ERLIN1 and interacts with key ER-resident proteins, such as Insig-1. to regulate sterol-regulated degradation of HMG-CoA reductase, a rate-limiting enzyme in cholesterol biosynthesis.
The recombinant ERLIN2 protein is engineered for in vitro studies to dissect its structural and functional properties. Produced using expression systems like *E. coli* or mammalian cell lines, recombinant ERLIN2 retains post-translational modifications (e.g., glycosylation) critical for its activity when expressed in eukaryotic systems. It is widely used to investigate its role in ER stress responses, lipid metabolism, and neurodegenerative disorders.
Mutations in the *ERLIN2* gene are linked to hereditary spastic paraplegia (HSP) and juvenile primary lateral sclerosis, highlighting its importance in neuronal health. Recombinant ERLIN2 enables research into disease mechanisms, drug screening, and therapeutic target validation. Its study also sheds light on ER membrane dynamics and protein quality control pathways, offering insights into broader cellular processes and potential interventions for lipid-related pathologies.
×
